Description:
Phase 1/2a Clinical Trial of BI-1206, a Monoclonal Antibody to CD32b (FcγRIIB), in
Combination with Pembrolizumab in Subjects with Advanced Solid Tumors Previously Treated with
Anti-PD-1 or Anti-PD-L1 Antibodies
Title
- Brief Title: A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors (KEYNOTE-A04)
- Official Title: A Phase 1/2a Clinical Trial of BI-1206, a Monoclonal Antibody to CD32b (FcγRIIB), in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors Previously Treated With Anti-PD-1 or Anti-PD-L1 Antibodies (KEYNOTE-A04)
Clinical Trial IDs
- ORG STUDY ID:
18-BI-1206-03
- NCT ID:
NCT04219254
Conditions
Interventions
Drug | Synonyms | Arms |
---|
Pembrolizumab 25 MG/ML(MK-3475) | | BI-1206 |
Purpose
Phase 1/2a Clinical Trial of BI-1206, a Monoclonal Antibody to CD32b (FcγRIIB), in
Combination with Pembrolizumab in Subjects with Advanced Solid Tumors Previously Treated with
Anti-PD-1 or Anti-PD-L1 Antibodies
Detailed Description
This is a Phase 1/2a, multicenter, dose-finding, consecutive-cohort, open-label trial of
BI-1206 in combination with pembrolizumab in subjects with advanced solid tumors who have
previously received treatment with a PD-1/PD-L1 immune checkpoint inhibitor.
The trial will consist of 2 main parts: Phase 1 (with dose escalation cohorts and selection
of the RP2D), and Phase 2a (with 3 expansion cohorts at the RP2D).
Subjects in each phase will initially receive 3 planned doses of therapy with BI-1206 in
combination with pembrolizumab.
Subjects who show clinical benefit (CR, PR or SD) at the Week 9 Visit may continue on
combination therapy. Starting at Week 10, these subjects will receive infusions every 3 weeks
for up to 32 additional doses or up to 2 years from first dose of BI-1206 therapy or until
progression.
Trial Arms
Name | Type | Description | Interventions |
---|
BI-1206 | Experimental | BI-1206 administrated IV with a starting dose of 1 mg/kg every third week using mTPI2 Design in escalation Phase I. RP2D to be used i Phase IIa. | - Pembrolizumab 25 MG/ML(MK-3475)
|
Eligibility Criteria
Inclusion Criteria:
- Is willing and able to provide written informed consent for the trial.
- Is ≥18 years of age on day of signing informed consent.
- Has a histologically confirmed advanced solid tumor. Subjects must have received at
least 2 doses of an approved anti-PD-1/L1 mAb, and have documented progression on or
within 12 weeks from the last dose of anti-PD-1/L1 mAb.
- Is intolerant of, refuses, or is not eligible for standard antineoplastic therapy.
- Has at least 1 measurable disease lesion as defined by Response Evaluation Criteria in
Solid Tumors
- Is able to safely undergo a baseline tumor tissue biopsy prior to first dose of
BI-1206
- Has a life expectancy of ≥12 weeks.
- Has an ECOG performance status of 0-1.
- Has adequate organ function as confirmed by laboratory values listed in the main body
of the protocol
Expansion Cohort-Specific Inclusion Criteria:
In addition to the general inclusion criteria above, subjects must also meet the criteria
for the specific cohort.
- Cohort 1 (Non-small cell lung cancer):
- For subjects whose tumor has PD-L1 ≥ 50%: Required prior therapies will include
anti-PD-1 therapy as monotherapy. Prior standard of care chemotherapy will be
allowed but not required.
- For tumors with unknown PD-L1 or PD-L1 < 50% , required prior therapies will
include anti-PD 1/PD-L1 therapy and SOC chemotherapy either combined with anti
PD-1/PD-L1 therapy or given separately.
- For subjects with known anaplastic lymphoma kinase, ROS1 or epidermal growth
factor receptor sensitizing molecular rearrangements, one line of targeted
therapy will be required in addition to anti-PD-1/PD-L1 therapy.
- Cohort 2 (Metastatic Melanoma):
- Required prior therapies will include anti-PD-1 therapy either as monotherapy or
as part of a combination regimen.
- For subjects with a known BRAF V600-activating mutation combination targeted
therapy will be required in addition to anti-PD-1/PD-L1 therapy.
- Cohort 3 (Other Tumor Types):
- All subjects will require prior anti-PD-1/PD-L1 therapy
Exclusion Criteria:
- Needs doses of prednisolone >10 mg daily (or equipotent doses of other
corticosteroids)
- Has known active central nervous system (CNS) metastases and/or carcinomatous
meningitis.
- Has known or suspected hypersensitivity to pembrolizumab or BI-1206 or any of their
excipients.
- Has cardiac or renal amyloid light-chain (AL) amyloidosis.
- Has received the following:
- Chemotherapy or small molecule products within 4 weeks of first dose of BI 1206.
- Radiotherapy within 2 weeks of first dose of BI-1206. A 1-week washout is
permitted for palliative radiation (≤2 weeks of radiotherapy) for non-CNS
disease. Subjects who have previously had radiation pneumonitis are not allowed.
- Immunotherapy within 4 weeks prior to the first dose of BI-1206.
- Has not recovered from AEs to at least Grade 1 by Common Terminology Criteria for
Adverse Events v4.0 due to prior anti-cancer therapies.
- Has had Grade ≥3 autoimmune manifestations of previous immune checkpoint inhibitor
treatments .
- Has a history of (non-infectious) pneumonitis that required steroids or has current
pneumonitis.
- Has an active, known or suspected autoimmune disease.
- Is a female subject and has the ability to become pregnant (or already pregnant or
lactating/ breastfeeding). o Intravaginal
- Is a male subject with partner(s) of child-bearing potential• Has had major surgery
from which the subject has not yet recovered.
- Is at high medical risk because of non-malignant systemic disease including severe
active infections on treatment with antibiotics, antifungals or antivirals.
- Has presence of chronic graft versus host disease.
- Has had an allogenic tissue/solid organ transplant.
- Has known human immunodeficiency virus (HIV) and / or history of hepatitis B or C
infections, or has a positive test for HIV antibody, hepatitis B antigen / hepatitis B
virus DNA or hepatitis C antibody or RNA.
- Has a history of active tuberculosis (bacillus tuberculosis).
- Has received a live vaccine within 30 days before the first dose of study treatment.
- Has uncontrolled or significant cardiovascular disease
- Has a known psychiatric or substance abuse disorder that would interfere with the
subject's ability to cooperate with the requirements of the study.
- Has a history or current evidence of any condition, therapy, or laboratory abnormality
that might confound the results of the study, interfere with the subject's
participation for the full duration of the study, or is not in the best interest of
the subject to participate, in the opinion of the treating investigator.
- Is participating or planning to participate in another interventional clinical trial,
or has participated in a trial of an investigational agent or has used an
investigational device within 4 weeks prior to first dose of study drug. Subjects who
have entered the follow-up phase of an investigational study may participate as long
as it has been 4 weeks after the last dose of the previous investigational agent.
Participation in an observational trial is acceptable.
- Has a known additional malignancy of another type
- Has a diagnosis of primary or acquired immunodeficiency disorder or taking any other
form of immunosuppressive therapy within 7 days prior the first dose of study drug.
Maximum Eligible Age: | N/A |
Minimum Eligible Age: | 18 Years |
Eligible Gender: | All |
Healthy Volunteers: | No |
Primary Outcome Measures
Measure: | Documenting AEs and SAEs and determining causality in relation to BI-1206 and/or pembrolizumab |
Time Frame: | Up to 2 year |
Safety Issue: | |
Description: | Assess the safety and tolerability profile of increasing doses of BI-1206 in combination with pembrolizumab, graded according to National Cancer Institute [NCI]-CTCAE version 4.0 |
Secondary Outcome Measures
Measure: | Evaluation of PK parameters for BI-1206. Maximum observed plasma concentration (Cmax) |
Time Frame: | Up to 2 year |
Safety Issue: | |
Description: | Study the PK profile of BI-1206 according to a non-compartmental analysis using a validated software |
Measure: | Evaluation of PK parameters for BI-1206. Area under the plasma concentration-time curve (AUC) |
Time Frame: | Up to 2 year |
Safety Issue: | |
Description: | Study the PK profile of BI-1206 according to a non-compartmental analysis using a validated software |
Measure: | Evaluation of ADA response to BI 1206 |
Time Frame: | Up to 2 year |
Safety Issue: | |
Description: | Assess the immunogenicity of BI-1206. Detection and characterization of antibodies to BI-1206 will be performed using a validated method and will be evaluated for BI-1206 serum concentration to enable interpretation of the antibody data. |
Measure: | Measurement of CD32b receptor occupancy on B cells. |
Time Frame: | Up to 2 year |
Safety Issue: | |
Description: | Evaluate the effect of BI-1206 administered in combination with pembrolizumab on CD32b receptor occupancy on B cells in subjects with advanced solid tumors. |
Details
Phase: | Phase 1/Phase 2 |
Primary Purpose: | Interventional |
Overall Status: | Recruiting |
Lead Sponsor: | BioInvent International AB |
Last Updated
August 11, 2021